Active Ingredient History
Ceritinib is a selective inhibitor of ALK1, a target found in metastatic non-small cell lung cancer (NSCLC). Ceritinib is approved by FDA and is indicated for the treatment of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer. Ceritinib also targets insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (InsR), and ROS1. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Antigens, CD (Phase 1/Phase 2)
Biomarkers (Phase 2)
Brain Neoplasms (Early Phase 1)
Carcinoma, Hepatocellular (Phase 2)
Cholangiocarcinoma (Phase 2)
Colorectal Neoplasms (Phase 2)
Esophageal Neoplasms (Phase 2)
Glioblastoma (Phase 2)
Hematologic Neoplasms (Phase 2)
Liver Diseases (Phase 1)
Lung Neoplasms (Phase 2)
Lymphoma, Large-Cell, Anaplastic (Phase 2)
Melanoma (Phase 2)
Neoplasms ()
Neuroblastoma (Phase 2)
Oncogene Proteins (Phase 2)
Oncogenes (Phase 2)
Pancreatic Neoplasms (Phase 2)
Proto-Oncogene Proteins B-raf (Phase 2)
Proto-Oncogene Proteins c-met (Phase 2)
ras Proteins (Phase 2)
Sarcoma (Phase 3)
Stomach Neoplasms (Phase 2)
Thyroid Neoplasms (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue